Better Obesity Drug Race: Novo Nordisk vs Lilly 2026
In the race to dominate obesity drugs, Novo Nordisk and Eli Lilly are frontrunners. This guide analyzes who has the e...
A short examination of how index fund return variance evolves across decades and what it means for risk budgets.
25,652 articlesIn the race to dominate obesity drugs, Novo Nordisk and Eli Lilly are frontrunners. This guide analyzes who has the e...
In the first half of 2026, Upstart stock fell about 19%, shaking confidence in a fintech darling. This article breaks...
A major stake sale in Arcellx coincides with fresh competition in the field. This analysis breaks down what happened,...
Investors are watching a handful of tech names retreat despite strong long term potential. This guide explains how be...
As oil reserves dwindle, two big trends are shaping energy markets in 2026. This article breaks down what to watch, w...
New disclosures reveal a large, ongoing cash burn tied to Elon Musk’s AI push, exposing capital risks for SpaceX-xAI ...
What happens when AI breakthroughs and high-flying tech bets collide with political markets? This article explains th...
A high-stakes move by a leading investment manager has turned heads in the tech infrastructure space. This article ex...
A venture-backed biotech startup unveils a plan to collect genomic data from 100 million species to fuel AI drug disc...
Friday brought a surprising turn for Bitcoin as it slipped alongside rising yields and shifting market sentiment. Thi...
SpaceX going public soon would shake investor interest in the space economy. This guide shows how to position yoursel...
A prominent investor labels SpaceX’s lofty value as bubblicious, arguing that Starlink’s progress alone may not justi...